Key Drivers
- Strong Profitability
- Weak Cash Flow
- Thin Liquidity
AIAI Summary
MD now looks less like a simple cheap, stable healthcare name and more like a company that can still drive earnings upside from pricing, payer mix, and collections even with soft volumes, but the latest quarter's negative operating/free cash flow means the stock should only re-rate if that earnings strength starts converting into durable cash generation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Profitability
- •Weak Cash Flow
- •Thin Liquidity
MD shows solid annual profitability and a low valuation, but weak near-term cash conversion, thinner liquidity, and an intangible-heavy balance sheet warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Range-bound action
- •Support holding
- •Resistance capped
- •Technical Levels:
- •Support Level: $22.20-$22.50
- •Resistance Level: $23.70-$24.00
- •Anomalous Movement: Brief drop to $20.83 quickly reversed, followed by a rebound to $23.98 that later faded.
Over the last month, MD has stayed range-bound between roughly $22 and $24, with buyers defending $22.20-$22.50 and sellers capping rallies near $23.70-$24.00, so a break below support could retest $20.83 while a reclaim of $23.98 would strengthen the bullish case.
Sentiment & News
Key News Insights:
- •Earnings beat
- •Cash collections
- •Margin expansion
Pediatrix Medical Group posted a strong Q1 beat, reaffirmed its full-year EBITDA outlook, and continues to show improving profitability and cash generation despite softer patient volumes.
The news is likely supportive for MD, as stronger pricing, better payer mix, and reaffirmed guidance reinforce the stock's positive operating momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings